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Abstract
Gut microbiota-related metabolites are potential clinical biomarkers for cardiovascular disease (CVD). Circulating succinate, a
metabolite produced by both microbiota and the host, is increased in hypertension, ischemic heart disease, and type 2 diabetes.
We aimed to analyze systemic levels of succinate in obesity, a major risk factor for CVD, and its relationship with gut
microbiome. We explored the association of circulating succinate with specific metagenomic signatures in cross-sectional and
prospective cohorts of Caucasian Spanish subjects. Obesity was associated with elevated levels of circulating succinate
concomitant with impaired glucose metabolism. This increase was associated with specific changes in gut microbiota related to
succinate metabolism: a higher relative abundance of succinate-producing Prevotellaceae (P) and Veillonellaceae (V), and a
lower relative abundance of succinate-consuming Odoribacteraceae (O) and Clostridaceae (C) in obese individuals, with the
(P+V/O+C) ratio being a main determinant of plasma succinate. Weight loss intervention decreased (P+V/O+C) ratio
coincident with the reduction in circulating succinate. In the spontaneous evolution after good dietary advice, alterations in
circulating succinate levels were linked to specific metagenomic signatures associated with carbohydrate metabolism and energy
production with independence of body weight change. Our data support the importance of microbe–microbe interactions for the
metabolite signature of gut microbiome and uncover succinate as a potential microbiota-derived metabolite related to CVD risk.
Introduction
Cardiovascular disease (CVD) is a collective term used to
describe heart and blood vessel disorders and constitutes the
leading cause of death worldwide. In developed countries,
CVD usually manifests as coronary artery disease, athero-
sclerosis, and hypertension, with central obesity playing an
increasingly important role as a risk factor [1].
Although much attention has focused on the generation of
reactive oxygen species and consequent downstream ramifi-
cations in the progression of CVD [2], more studies are now
centering on the human metabolome as a potential resource of
biomarkers of CVD and also as novel therapeutic targets [3].
Against this background, the tricarboxylic acid intermediate
succinate is concentrated in body fluids under conditions of
hypoxia and inflammation where it serves as a universal
metabolic signal of local stress and immunologic danger
[4–6]. Accordingly, elevated levels of circulating succinate
have been detected in several high-risk CVD states such as
hypertension [7], ischemic heart disease [8], and type 2 dia-
betes mellitus (T2DM) [7, 9–11]. Under these scenarios,
extracellular succinate is thought to signal through its cognate
receptor SUCNR1/GPR91, with pathological implications in
hypertrophic cardiomyopathy [8], obesity-related metabolic
disturbances [12], renin-induced hypertension [10], and dia-
betic retinopathy [13].
There is a lack of consensus regarding the origin of
circulating succinate. Although it is probable that damaged
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tissues contribute to the succinate found in circulation [13,
14], it is not unreasonable to expect that a relevant source of
extracellular succinate might be attributed to intestinal
efflux by specific gut microbiota, consistent with the
ancestral bacterial origin of mitochondria. Traditionally
described as a key intermediate in microbial propionate
synthesis, succinate is a natural metabolic end product in
some bacteria [15]. Remarkably, recent studies show that
colonization of germ-free mice with the well-known suc-
cinate producer Prevotella copri increases cecal succinate,
which improves glycemic control through activation of
intestinal gluconeogenesis [16, 17].
Dysbiosis of the gut microbiota is associated with CVD and
its traditional risk factors T2DM, insulin resistance, and obe-
sity [15, 18–20]. Products of bacterial metabolism have been
associated with both health benefits and disease. Thus, short
chain fatty acids (SCFAs) produced via fermentation of non-
digestible carbohydrates by colonic microbiota have been
reported to enter systemic circulation [15, 21] and reach per-
ipheral tissues, where they can activate their cognate receptors
[21], improving body composition, glucose, and lipid home-
ostasis [22, 23]. Indeed, dietary SCFA supplementation was
shown to decrease atherosclerotic lesions in murine models
[24]. Conversely, other gut microbial-derived metabolites such
as trimethylamine and trimethylamine N-oxide (TMAO) are
proatherogenic [25, 26] and have emerged as prognostic
markers for incident cardiovascular events [27]. By analogy,
we postulate that other organic acids such as succinate might
be released by gut commensal bacteria into circulation, parti-
cularly in pathological conditions associated with an increase
in intestinal permeability (leaky gut), such as obesity [28]. To
the best of our knowledge, no studies have linked gut
microbiota to circulating succinate. Here, we show that cir-
culating succinate levels are increased in obesity and can be
characterized by a specific intestinal bacterial signature.
Weight loss alters the composition of succinate-producing and
-consuming gut microbiota, which is coincident with a
reduction in circulating levels of succinate. More importantly,
spontaneous changes in intestinal succinate-metabolizing
microbiota (producers vs. consumers) over a 2-year period
are paralleled with changes in circulating succinate, with
independence of weight loss, indicating a strong link between
specific microbiome signature and blood succinate levels.
Materials and methods
Study design and patients
The present study comprised five different clinical sub-
studies to serve the following different aims: (1) analyze
circulating succinate levels in lean, obese, and diabetic
subjects using a cross-sectional study, cohort I; (2) examine
the relationship between gut microbiota and succinate
(discovery cohort II and confirmatory cohort III); (3)
establish a link between circulating succinate and gut
microbiota (dietetic intervention study cohort IV and
follow-up study cohort V).
All studies were conducted in accordance to the princi-
ples of the Declaration of Helsinki. All volunteers received
information concerning their participation in the study and
gave written informed consent. The studies were approved
by the respective local ethics committee review boards of
the participating Hospitals.
Inclusion criteria for all subjects
(1) Caucasian men and women; (2) body mass index (BMI)
range from lean to obese (adequately represented in each
group); (3) absence of underlying pathology on physical
examination and tests other than those associated with an
excess of weight or diabetes; and (4) signed informed
consent for participation in the study.
Exclusion criteria for all subjects
(1) Serious systemic disease unrelated to obesity such as
cancer, severe kidney, or liver disease; (2) systemic diseases
with intrinsic inflammatory activity; (3) history of liver dis-
ease (chronic active hepatitis or cirrhosis) and/or abnormal
liver function (alanine transaminase and/or aspartate transa-
minase three times above the upper normal value); altered
renal function (creatinine >1.4 mg/dl in women and 1.5 mg/dl
in men); (4) pregnancy and lactation; (5) vegetarians or sub-
jects subjected to irregular diet; (6) patients with severe dis-
orders of eating behavior; (7) clinical symptoms and signs of
infection in the previous month; (8) anti-inflammatory chronic
treatment with steroidal and/or non-steroidal anti-inflamma-
tory drugs; (9) prior antibiotic treatment in the last 3 months;
(10) major psychiatric antecedents; and (11) uncontrolled
alcoholism or drug abuse.




Ninety-one subjects (49 women and 42 men) were included
in the cross-sectional study (30 lean, 41 obese, and 20
patients with T2DM). Obesity was classified according to
World Health Organization (WHO) criteria. Patients with
T2DM were diagnosed according to American Diabetes
Association criteria with a stable metabolic control in the
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previous 6 months, as defined by stable glycosylated
hemoglobin values. No patient was insulin treated; 60%
were taking metformin, 20% were treated with sulfonylurea
and <15% were treated with dipeptidyl peptidase-4 inhibi-
tors. Subjects were recruited at the Endocrinology Service at
the University Hospital Joan XXIII (Tarragona, Spain).
Intervention
All patients had fasted overnight before collection of sub-
cutaneous adipose tissue (SAT) and blood. SAT was
obtained during scheduled non-acute surgical procedures
including laparoscopic surgery for hiatus hernia repair or
cholecystectomies. SAT samples were washed in
phosphate-buffered saline (PBS) and immediately frozen in
liquid N2 with storage at −80 °C, or used immediately for
fractionation. For SAT fractionation, fresh SAT was diced
into small pieces (10–30 mg), washed in PBS, and incu-
bated in Medium 199 (Gibco, Grand Island, NY) plus 4%
bovine serum albumin and 2 mg/ml collagenase type I
(Sigma-Aldrich, St. Louis, MO) for 1 h in a shaking water
bath at 37 °C. Anthropometrical and clinical variables are





Twenty female subjects were included in the cross-sectional
study (10 lean and 10 obese). Obesity was classified
according to WHO criteria. Subjects were recruited in the
outpatient surgery at the Endocrinology Service at the
University Hospital Virgen de la Victoria de Málaga
(Malaga, Spain). The study participants received no anti-
biotic treatment, probiotics, prebiotics, or any other medical
treatment influencing intestinal microbiota during the
3 months before the start of the study.
Intervention
All patients had fasted overnight before collection of blood
and stool. Anthropometrical and clinical variables are





Seventeen subjects (10 women and 7 men) were included in
the study (9 lean and 8 obese). Obesity was classified
according to WHO criteria. Subjects were recruited at the
Endocrinology Service at the University Hospital Dr. Josep
Trueta (Girona, Spain). The study participants received no
antibiotic treatment, probiotics, prebiotics, or any other
medical treatment influencing intestinal microbiota during
the 3 months before the start of the study.
Intervention
All patients had fasted overnight before collection of blood
and stool. Anthropometrical and clinical variables are
summarized in Supplementary Table S2.




Nine obese women (a subsample of the registered study
ISRCTN88315555) were included in the study. Subjects
were recruited in the outpatient surgery at the Endocrinol-
ogy Service at the University Hospital Virgen de la Victoria
de Málaga. The study participants received no antibiotic
treatment, probiotics, prebiotics, or any other medical
treatment influencing intestinal microbiota during the
3 months before the start of the study.
Intervention
Patients underwent an intervention involving a hypocaloric
Mediterranean Diet and physical exercise program. The
Mediterranean Diet included extra virgin olive oil and nuts
and reduced the energy intake by approximately 600 kcal.
The diet comprised fat (35–40%; 8–10% saturated fatty
acids), carbohydrates (40–45%; low glycemic index), and
protein (20%) [29, 30]. Adherence to the diet was measured
as described previously [31]. Participants were encouraged
to gradually increase their level of physical activity to reach
at least 45 min per day over the course of the study, which
was assessed by their personal trainer on a monthly basis.
Participants kept a physical activity record using a GEN-
EActiv© accelerometer. Physical activity levels were eval-
uated using the Rapid Assessment of Physical Activity
questionnaire [32].
Dietary and physical intervention involved individual
visits with a nutritionist every week during the 3 months.
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Furthermore, a nutritional education program was initiated
to modify dietary and lifestyle habits with the aim of pro-
moting both weight loss and subsequent weight main-
tenance. All patients had fasted overnight before collection
of blood and stool, before and after the intervention.
Anthropometrical and clinical variables are summarized in
Supplementary Table S3. None of the nine volunteers
received antibiotic therapy, prebiotics, probiotics, synbio-
tics, vitamin supplements, or any other medical treatment
influencing intestinal microbiota during the 3 months before
the start of the study or during the study.
Follow-up study cohort V
Design
Spontaneous observational follow-up study.
Participants
Nineteen patients were followed for 2 years to evaluate the
spontaneous evolution of the microbiota. General counsel-
ing was provided to the subjects. None of the 19 volunteers
received antibiotic therapy, prebiotics, probiotics, synbio-
tics, vitamin supplements, or any other medical treatment
influencing intestinal microbiota in the 3 months before the
start of the study or during the study (2 years). All patients
had fasted overnight before collection of blood and stool
samples, before and after the follow-up period. Anthro-
pometrical and clinical variables are summarized in Sup-
plementary Table S4.
Analytical determinations
Blood samples were drawn after a 12-h fast. Serum/plasma
was separated and immediately frozen at −80 °C. Serum
biochemical parameters were measured in duplicate. Serum
glucose, cholesterol, high density lipoprotein (HDL) cho-
lesterol and triglycerides were measured by standard enzy-
matic methods (Randox Laboratories Ltd, Antrim, UK).
Insulin was measured with an immunoradiometric assay
(BioSource International, Camarillo, CA).
Gene expression analysis
Total RNA was extracted from SAT using the RNeasy
Lipid Tissue Midi Kit (Qiagen, Hilden, Germany). Total
RNA quantity was measured at 260 nm and purity was
assessed by the OD260/OD280 ratio. For gene expression
analysis, 1 μg of RNA was reverse transcribed with random
primers using the Reverse Transcription System (Applied
Biosystems, Foster City, CA). For microRNA analysis,
complementary DNA (cDNA) synthesis was performed
with the TaqMan MicroRNA Reverse Transcription Kit
(Thermo Fisher Scientific, Waltham, MA). Real-time PCR
(qPCR) was conducted on a 7900HT Fast Real-Time PCR
System using TaqMan Gene Expression Assays (Applied
Biosystems) for ATGL (Hs 00386101_m1), ZAG (Hs
00426651_m1), ABHD5 (Hs01104373), HSL (Hs
00193510_m1), CD163 (Hs00174705_m1), HIF1A
(Hs00153153_m1), IL1B (Hs001749097_m1), and CCL2
(Hs00234140_m1). Results were calculated using the
comparative Ct method (2-ΔΔCt) and expressed relative to
the expression of the housekeeping gene 18S (Hs
03928985_g1).
Fecal microbiome analysis
16S sequencing (cohort II and IV)
Collected stool samples were immediately frozen at −80 °
C. Genomic DNA was extracted following the recom-
mendations of the International Human Microbiome
Standards (http://www.microbiome-standards.org) [33]. A
frozen aliquot (250 mg) of each sample was suspended in
250 ml of guanidine thiocyanate, 40 ml of 10% N-lauroyl
sarcosine, and 500 ml of 5% N-lauroyl sarcosine. DNA
was extracted by mechanical disruption of the microbial
cells with beads, and nucleic acids were recovered from
clear lysates by alcohol precipitation. An equivalent of 1
mg of each sample was used for DNA quantification using
a spectrophotometer (NanoDrop Technologies, Wilming-
ton, DE). DNA integrity was examined by micro-capillary
electrophoresis using an Agilent 2100 Bioanalyzer with
the DNA 12,000 Kit, which resolves the distribution of
double-stranded DNA fragments up to 17,000 bp in
length. Ribosomal 16S rRNA gene sequences were
amplified from cDNA using the 16S Metagenomics Kit
(Thermo Fisher Scientific, Italy). The kit included two
primer sets that selectively amplify the corresponding
hypervariable regions of the 16S region in bacteria: pri-
mer set V2–4–8 and primer set V3–6, 7–9. The PCR
conditions used were 10 min at 95 °C, 30 cycles of 30 s at
95 °C, 30 s at 58 °C, and 20 s at 72 °C, followed by 10 min
at 72 °C. The concentration and the average size of each
amplicon was determined using the Quant-iT PicoGreen
dsDNA Assay Kit (Invitrogen); the amount of DNA
fragments per microliter was calculated and libraries were
created using the Ion Plus Fragment Library Kit (Thermo
Fisher Scientific). Barcodes were added to each sample
using the Ion Xpress Barcode Adapters 1–16 kit (Thermo
Fisher Scientific). The library concentrations were deter-
mined using the Ion Universal Library Quantification Kit
(Thermo Fisher Scientific). Emulsion PCR and sequen-
cing of the amplicon libraries was performed on a Ion 520
chip (Ion 520™ Chip Kit) using the Ion Torrent S5™
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system and the Ion 520™/530™ Kit-Chef (Thermo Fisher
Scientific) according to the manufacturer´s instructions.
After sequencing, the individual sequence reads were
filtered using Ion Reporter Software V4.0 to remove low
quality and polyclonal sequences.
Metagenomic analysis (cohort III and V)
Total DNA was extracted from frozen human stool
samples using the QIAamp DNA Stool Mini Kit (Qiagen,
Courtaboeuf, France). Quality assessment was performed
with the prinseq-lite program applying the following
parameters: min_length, 50, trim_qual_right, 20, trim_-
qual_type, mean; and trim_qual_window, 20. R1 and R2
reads from Illumina sequencing were joined using fastq-join
from ea-tools suite. The fastq files were converted into
fasta files using the ‘fastq_to_fasta’ tool from the FastX-
Toolkit program. Those files were filtered against the
human genome, downloaded from the NCBI FTP site
(ftp://ftp.ncbi.nlm.nih.gov/genomes/H_sapiens/). The una-
ligned files, that is, those that did not map against the
human genome, were the input files of a BLASTn search
against a customized bacterial database (Bac-
teria_2015_06_09) consisting of the Human Microbiome
and the bacterial genomes downloaded from the NCBI FTP
site (ftp://ftp.ncbi.nlm.nih.gov/genomes/ HUMAN
MICROBIOM/Bacteria/ and ftp://ftp.ncbi.nlm. nih.gov/
genomes/archive/old_refseq/Bacteria/). The best hits of the
BLASTn output files were extracted, converted into con-
tingency tables, and transformed into BIOM format to be
used as input files of the Quantitative Insights Into Micro-
bial Ecology (QIIME) open-source software pipeline ver-
sion 1.9.0 [34, 35].
Circulating succinate measurement
Fluorimetric method
Circulating serum/plasma succinate levels were measured
using the EnzyChromTM Succinate Assay Kit (BioAssay
Systems, Hayward, CA). The assay sensitivity was 12 µM
and the intra- and interassay coefficients of variance were
<3.5 and 6.95%, respectively.
LC-MS/MS and NMR analysis
We validated circulating succinate levels obtained by the
fluorimetric assay using liquid chromatography tandem-
mass spectrometry (LC-MS/MS) and nucelar magnetic
resonance (NMR) analysis. To do this, a subsample of
plasma samples from cohort I was prepared as previously
reported with some modifications [36, 37]. Importantly, the
concentration of succinic acid measured by the fluorimetric
assay correlated with that measured by LC-MS/MS (r=
0.617, p= 0.019) and by NMR (r= 0.769, p= 0.043),
indicating that we could use the fluorimetric assay to
measure human succinate levels, which is faster and more
economical than the other two methodologies.
Circulating zonulin measurement
We measured serum zonulin as a surrogate marker of
intestinal permeability. Circulating plasma/serum zonulin
levels were assessed using the Human Zonulin Elisa Kit
(MyBiosource, San Diego, CA) [38, 39]. This assay has
high sensitivity (1 ng/ml) and excellent specificity for
detection of zonulin, and only detects the active (uncleaved)
form. The intra- and interassay coefficients of variation for
these determinations were <10%.
Statistical analysis
Statistical analysis was performed with the Statistical
Package for the Social Sciences software, version 15 (SPSS,
Chicago, IL). For clinical and anthropometrical variables,
normally distributed data were expressed as mean± SD and
for variables with no Gaussian distribution values were
expressed as median (25th–75th quartiles). Student’s t-test
with Bonferroni adjustment was used to compare the mean
value of normally distributed continuous variables. For
variables that did not have a Gaussian distribution, we used
the Kruskal–Wallis test with post hoc Dunn’s multiple
comparison test. To analyze the differences in nominal
variables between groups, we used the χ2 test. For micro-
biota data, statistical significance was tested by unpaired
t-test or Mann–Whitney U-test as part of the SPSS
software package. For intervention studies, Wilcoxon
signed-rank test or paired t-test was used for paired
analysis in the two prospective cohorts as appropriate.
Pearson’s and Spearman’s correlation coefficients with
Bonferroni adjustment were used to analyze the relationship
between parameters. To determine which variables were
associated with circulating succinate, multiple linear
regression analyses were employed (stepwise forward
selection procedures). All variables associated in the uni-
variate analysis with succinate were included in their
respective models. A p-value <0.05 was considered sig-
nificant. For functional studies, statistical analysis was
performed with R statistics software version 3.3.3. Wil-
coxon rank-sum test was used for hypotheses testing ana-
lysis between the two groups (group 1 vs. group 2). Heat
maps were generated using a hierarchical clustering algo-
rithm to visualize the metagenomic function and metabolite
differences within the data set.
Elevated circulating levels of succinate in human obesity...
C. Serena et al.
Results and Discussion
Circulating levels of succinate are elevated in
obesity and associated with a worse metabolic
profile
In a cohort of 91 patients stratified according to obesity and
T2DM (cohort 1), plasma succinate levels were sig-
nificantly higher in obese than in lean individuals (Fig. 1a,
Supplementary Table S1), and a comparable increase was
detected in BMI-matched T2DM patients, in line with a
recent report [11]. These results suggest that systemic suc-
cinate is also associated with body weight status. Accord-
ingly, we found a positive association between circulating
succinate levels and BMI (Fig. 1b), but also insulin, glu-
cose, homeostasis model assessment of insulin resistance
(HOMA-IR), and triglycerides (Fig. 1b). Consistent with
the documented role of succinate in blood pressure reg-
ulation [7, 40], circulating succinate also correlated posi-
tively with diastolic blood pressure (R= 0.386, p= 0.039).
A multiple regression analysis model (R2= 0.295) adjusted
for age and gender showed that BMI and glucose (β=
0.495 p< 0.001 and β= 0.279 p= 0.013, respectively)
were the main determinants of circulating succinate levels.
Succinate has been shown to have antilipolytic actions in
adipose tissue via engagement with SUCNR1, inhibiting the
release of fatty acids from adipocytes [12, 41]. Consistent
with this scenario, metabolic gene expression profiling in
SAT from a representative subset of cohort I (n= 42)
revealed a negative association between systemic succinate
levels and genes encoding key enzymes involved in intra-
cellular degradation of triacylglycerols, including adipose
triglyceride lipase (ATGL), abhydrolase domain containing
(ABHD5), and hormone-sensitive lipase (HSL) (Fig. 1c). A
similar negative association was found for the gene
encoding the secreted AT lipolytic factor zinc-alpha-2-
glycoprotein (ZAG) (Fig. 1c). Conversely, we found a
positive association between succinate and hypoxia-
inducible factor HIF-1α (Fig. 1d), a key transcription fac-
tor underlying chronic inflammation and AT dysfunction in
obesity [42, 43]. Indeed, a clear function for succinate has
been established in innate immune signaling, where it
enhances interleukin-1 beta (IL-1β) production via stabili-
zation of HIF-1α [6, 44]. Nevertheless, we found that sys-
temic succinate levels were associated with the expression
of the anti-inflammatory macrophage marker CD163 in
SAT (Fig. 1d), but not with inflammatory markers such as
IL-1β or MCP-1 (R= 0.116 p= 0.466; R= 0.039 p=
0.809, respectively), supporting the notion that succinate
might have differential intracellular and extracellular func-
tions as previously noted for other stress-related factors
such as osteopontin [45, 46] and heat shock proteins [47].
Of note, although some associations were also found in
visceral adipose tissue, stronger correlations were detected
in SAT, suggesting that the subcutaneous fat depot is more
responsive to succinate than visceral fat.
Gut microbiota composition is associated with
circulating succinate levels
In an independent cohort (cohort II, clinical, and anthro-
pometrical characteristics are summarized in Supplementary
Table S2), the serum concentration of succinate was sig-
nificantly higher in obese than in non-obese individuals
(43.93± 6.16 μM vs. 23.2± 1.57 μM, p= 0.0020). Of
note, the concentration of succinate in serum is about one-
third lower than that found in plasma ([13] and this study).
Analysis of gut microbiota composition by 16S rRNA
gene sequencing revealed an increase in the Firmicutes/
Bacteroidetes ratio in obese subjects (Supplementary Fig-
ure 1A), and decreased richness and biodiversity at the
phylum and genus level (Supplementary Figure 1B–C) [48–
51]. We found that the relative abundance (RA) of Pre-
votellaceae (37.52± 3.86% vs. 12.93± 3.97%, p= 0.0005)
and Veillonellaceae (36.08± 9.52% vs. 19.51± 4.26%, p
= 0.03), known succinate producers [20, 52, 53], was
higher in obese than in non-obese individuals (Fig. 2a).
Accordingly, serum succinate levels positively correlated
with Prevotellaceae (R= 0.465; p= 0.039). Conversely,
the RA of Odoribacteraceae (1.58± 0.68% vs. 6.18±
1.64%, p= 0.005) and Clostridaceae (0.09± 0.04% vs.
1.02± 0.36%, p= 0.05) families, known succinate con-
sumers [54, 55], was significantly lower in obese than in
non-obese individuals (Fig. 2a). No differences were
detected in other bacterial families such as Para-
prevotellaceae, Bacteroidaceae, or Ruminococcaceae,
which are also related to succinate metabolism [52, 54, 56–
58]. Consequently, the ratio of (Prevotellaceae+ Veillo-
nellaceae/Odoribacteraceae+ Clostridaceae) (fam(P+V/
O+ C)), specific succinate producers per consumers, was
significantly higher in obese subjects (Fig. 2b) and corre-
lated positively with succinate serum levels (Fig. 2c). At the
genus level, we found that the succinate-producing member
Mitsuokella spp. was enriched in fecal samples of obese
Fig. 1 Circulating succinate levels are increased in obesity and type 2
diabetes. a Circulating plasma levels in lean, obese and type 2 diabetes
(T2DM) individuals. Data are expressed as median and interquartile
range. Differences were analyzed by the Kruskal–Wallis test with post
hoc Dunn’s multiple comparison test. *p< 0.0001 vs. lean. b Positive
correlation between succinate levels and BMI, insulin, glucose,
HOMA-IR, and triglycerides using the entire cohort. c Negative cor-
relation between succinate levels and levels of SAT ATGL, SAT
ABHD5, SAT HSL, and SAT ZAG. d Positive correlation between
succinate levels and SAT HIF1A and SAT CD163. SAT; subcutaneous
adipose tissue. Statistical analyses for b–d: Spearman’s correlation
analysis. See also Table Supplementary S1 for all clinical character-
istics of this cohort
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subjects (9.67± 5.37% vs. 0.11± 0.11%, p= 0.08), which
was accompanied by a significant decrease in the succinate-
consuming members Phascolarctobacterium spp. (7.27±
2.29% vs. 24.15± 6.12%, p= 0.018) and Odoribacter spp.
(0.8± 0.27% vs. 3.66± 1.81%, p= 0.017) (Supplementary
Figure 1D). Correspondingly, the ratio of specific succinate
producers/succinate consumers at the genus level was also
significantly higher in obese than in non-obese individuals
(Supplementary Figure 1E).
According to the “leaky gut” hypothesis, intestinal dys-
biosis characteristic of obesity is directly related to trans-
location of bacteria and their products into systemic
circulation [28]. As expected, circulating levels of zonulin,
a useful biomarker of intestinal permeability [59–62], were
significantly higher in obese than in non-obese individuals
(869.33± 199.013 ng/ml vs. 500.87± 44.61 ng/ml, p=
0.04). A positive correlation was found between serum
succinate and circulating zonulin (R= 0.61; p= 0.011)
(Fig. 2d), suggesting that akin to the elevated levels of
circulating lipopolysaccharide in obesity [63, 64], intestinal
permeability might be closely associated with the presence
of succinate in systemic circulation.
To further investigate the relationship between serum
succinate and the gut microbiome, we performed whole-
genome shotgun sequencing of fecal DNA in an indepen-
dent cohort (confirmatory cohort III; clinical and anthro-
pometrical characteristics summarized in Supplementary
Table S2). As noted in previous cohorts, succinate plasma
levels were significantly higher in obese than in lean indi-
viduals (101.72± 9.37 μM vs. 78.24± 4.4 μM, p= 0.043).
Furthermore, we detected a significant increase in the family
Veillonellaceae (2.37± 0.39% vs. 1.41± 0.24%, p=
0.043) in obese subjects (Fig. 2e), as well as a positive
correlation between Veillonellaceae and succinate levels in
plasma (R= 0.773; p< 0.001) (Fig. 2f). Accordingly, obese
subjects had a higher gen(P+V/O+ C) ratio (Fig. 2g),
which positively correlated with plasma succinate levels
(Fig. 2h). Similar to cohort II, obese individuals had higher
zonulin levels (Supplementary Table S2), which also posi-
tively associated with circulating succinate levels (R= 0.59;
p= 0.0152).
Overall, these data demonstrate that despite the inter-
individual heterogeneity, circulating succinate levels are
associated with specific components of gut microbiota.
Interestingly, the microorganisms linked to circulating
succinate levels have been previously related to CVD and/
or its risk factors. Thus, succinate-consuming genera such
as Odoribacter and Clostridium have been linked to a
decrease in clinical parameters associated with CVD risk
[65, 66]. By contrast, the Prevotella genus, which we found
to be increased in obese individuals, has been recently
associated with hypertension [67] and TMAO-induced
atherosclerosis [68, 69]. Along these lines, Chen and
colleagues have demonstrated that resveratrol modulates gut
microbiota by inhibiting the Prevotella genus, which in turn
induces a decrease in circulating TMAO levels [70],
pointing to gut microbiota as an attractive target for phar-
macological or dietary interventions to decrease the risk of
developing CVD.
Modification of gut microbiota by dietary weight
loss intervention affects circulating succinate levels
To determine whether diet-induced modifications in gut
microbiota could be reflected in variations in circulating
succinate levels, we carried out a prospective 12-week
dietary intervention study in obese patients aimed to weight
loss (cohort IV, Supplementary Table S3). Serum succinate
levels decreased after the intervention (Fig. 3a) in parallel
with an increase in genus and family richness (Supple-
mentary Figure 2A). Although no significant differences
were detected in genus or family diversity (Supplementary
Figure 2B), we identified a decrease in the Firmicutes/
Bacteroidetes ratio (Supplementary Figure 2C), similar to
that reported in a previous dietary weight loss intervention
study [71–73].
In accordance with the results of the two previous
cohorts (cohort II and III), we found a significant decrease
in the succinate-producing families Prevotellaceae (17.91
± 6.43% vs. 7.15± 2.47%, p= 0.019) and Veillonellaceae
(13.11± 2.76% vs. 3.73± 1.48%, p= 0.027) after the
dietary intervention (Fig. 3b). Comparable to that observed
in cohort III, we found a positive correlation between the
change in the incidence of Prevotellaceae ([Prevotellaceae]
post-intervention – [Prevotellaceae]basal) and succinate levels (R
= 0.751; p= 0.019) (Fig. 3c). Correspondingly, the fam(P
+V/O+ C) ratio significantly decreased after weight loss
(Fig. 3d) in parallel with a decrease in succinate, which was
reflected in a positive correlation between the change in the
fam(P+V/O+ C) ratio and the change in circulating suc-
cinate (post-intervention–basal) (Fig. 3e). Similar observa-
tions were found at the genus level (Supplementary
Figure 2D), and the gen(P+V/O+ C) ratio significantly
decreased after the intervention (Supplementary Figure 2E).
Taken together, these results indicate that a short-term
dietary weight loss intervention impacts different members
of the gut commensal community related to succinate
metabolism. Specifically, a decrease in succinate producers
concomitant with an increase in succinate consumers at two
taxonomic levels, which correlates with the decrease in
systemic succinate levels observed, pointing to circulating
succinate as a new dysbiosis-associated metabolite in the
context of obesity.
Remarkably, joint analysis of both microbiota cohorts
(cohort II and IV) validated the strong positive correlation
between the fam(P+V/O+ C) ratio and circulating serum
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succinate levels (n= 38, R= 0.646; p< 0.001). Reassur-
ingly, multiple regression analysis revealed that our pro-
posed ratio based on (succinate-producing) vs. (succinate-
consuming) families was the main determinant of systemic
succinate levels (R2= 0.744, β= 0.597; p= 0.007). Not-
withstanding these strong correlations, exactly how micro-
bial communities interact and use succinate is currently
unknown. Moreover, other microbial groups could be
responsible for succinate production (e.g., Succinovibrio
spp., Ruminococcus spp., or Fibrobacter succinogenes) and
consumption (e.g., Dialister spp., Phascolartobacterium
succinatutes) [52, 54, 56–58]. Nevertheless, our results
strongly link the specific fam(P+V/O+C) ratio to circu-
lating succinate.
Microbiota spontaneous evolution drives changes in
systemic succinate
Finally, to evaluate the spontaneous evolution of micro-
biota, we studied 19 subjects in whom general healthy
habits counseling was provided: at baseline and at 2 years
thereafter (see Materials and methods section, cohort V
description in Supplementary Table S4). No significant
differences in body weight were observed in these patients
Fig. 2 Obese gut microbiota composition is associated with circulating
succinate levels. a Percentage of incidence within Bacteroidetes and
Firmicutes families in non-obese and obese individuals. b Differences
between non-obese and obese individuals at the family level: families
(Prevotellaceae plus Veillonellaceae/Odoribacteriaceae plus Clos-
tridaceae) (fam(P+V/O+ C)) ratio. c Positive correlation between
succinate serum levels and fam(P+V/O+C) ratio. d Positive corre-
lation between succinate serum levels and circulating zonulin levels. e
Validation studies were performed using cohort III. Percentage of
incidence within Bacteroidetes and Firmicutes families in lean and
obese individuals. f Positive correlation between succinate plasma
levels and Veilloneaceae. g Differences between lean and obese
individuals in the fam(P+V/O+C) ratio in the cohort III study. h
Positive correlation between succinate serum levels and log fam(P+
V/O+ C)) ratio in the cohort III study. See also Supplementary
Table S2 for all clinical characteristics of cohorts II and III. Data
information: for a and e, values are expressed as mean± SD. For b
and g, data are represented in box and whisker plot format (whiskers:
min to max). Statistical analyses: Mann–Whitney U-test. *p< 0.05 vs.
non-obese or lean. For c, d, f and h Spearman’s or Pearson’s corre-
lation analysis with Bonferroni adjustment were used
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in the follow-up. We used a metagenomic approach rather
than 16S sequencing to analyze gut microbiota in this
cohort. At the end of follow-up, subjects were classified into
two groups in terms of changes in the ratio (succinate-
producing) vs. (succinate-consuming) families (group 1,
decreased ratio vs. group 2, increased ratio). A reduction in
fam(P+V/O+ C) was associated with a significant
decrease in succinate levels (Table 1, group 1), whereas a
significant increase in this ratio was related to a rise in
systemic succinate (Table 1, group 2). These results show
that variation in gut microbial composition independent of
body weight changes are directly related to circulating
succinate. Of note, elevated systemic succinate was paral-
leled with an impairment of glucose homeostasis, which
contrasts with recently reported findings in animal models
showing that microbiota-produced succinate is directly
related to an improvement of glucose homeostasis [16].
Indeed, high succinate levels have been associated with
various human pathological settings including CVD [8] and
T2DM [7, 9–11].
Multivariate analyses identified statistically significant
associations between the expression of 64 genes encoding
metabolic enzymes, and the fam(P+V/O+ C) ratio.
Hierarchical clustering of these metagenomic data and the
associations among fam(P+V/O+ C) ratio, circulating
succinate and succinate-related microbial species, identi-
fied two clusters (labeled as A and B in Fig. 4a) with a
clear relationship with the fam(P+V/O+ C) ratio (posi-
tive and negative correlations represented in green and
red, respectively), which was mostly reflected by succi-
nate levels. The metagenomic-derived clusters were also
confirmed when associations with Prevotellaceae and
Clostridaceae were analyzed, and a strong inverse rela-
tionship was detected. The main positive associations in
cluster A were with genes encoding metabolic enzymes
involved in amino-acid transport and metabolism ([E]),
whereas cluster B showed a predominance of associations
with genes related to energy production and conversion
([C]). Robust relationships with genes related to carbo-
hydrate transport and metabolism ([G]) were revealed in
both clusters. Interestingly, subclusters A1/A2 and B1/B2
were segregated on the basis of inverse associations with
Veillonellaceae and Clostridaceae. These results link the
fam(P+ V/O+ C) ratio, specific gut microbiota and cir-
culating succinate levels with a specific molecular entity
and metabolic function.
Fig. 3 Weight loss induced by dietary intervention modifies specific
gut microbiota and impacts circulating succinate levels. a Circulating
serum succinate levels in basal state and after a 12-week dietary
intervention (12-wDI) from cohort IV. b Percentage of incidence
within Bacteroidetes and Firmicutes families in obese individuals in
basal state and after 12-wDI. c Positive correlation between the change
in succinate serum levels (12-wDI[succinate]-basal[succinate]) and the
change in Prevotellaceae (12-wDI [% abundance Prevotellaceae]-
basal[% abundance Prevotellaceae]). d Differences between basal
state and 12-wDI in the fam(P+V/O+ C) ratio. e Positive correlation
between the change in succinate serum levels (12-wDI[succinate]-
basal[succinate]) and the change in the (12-wDI fam(P+V/O+
C)–basal fam(P+V/O+C)) ratio. See also Supplementary Table S3
for all clinical characteristics of cohort IV. Data information: for a and
b values are expressed as mean± SD. For d, data are represented in
box and whisker plot format (whiskers: min to max). Statistical ana-
lyses: Wilcoxon signed-rank test. *p< 0.05 vs. basal. For c and d,
Spearman’s correlation analysis with Bonferroni adjustment was used
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The differences in the gene expression profiles associated
with specific bacterial communities were also evident when
we classified the cohort into two groups according the fam
(P+V/O+ C) ratio (group 1 vs. group 2) (Supplementary
Figure 3 A). An increase in the abundance of genes
encoding enzymes associated with carbohydrate transport
and metabolism ([G]), such as pectate lyase (EC:4.2.2.2),
pectinesterase (EC:3.1.1.11) and glycosyl hydrolase
(EC:3.2.1.52) after 2 years of follow-up, was detected in
subjects in whom the fam(P+V/O+ C) ratio was increased
in parallel with an increase in succinate levels. Curiously, a
decrease in the abundance of genes encoding enzymes
connecting the pentose phosphate pathway to glycolysis,
such as ribulokinase (EC:2.7.1.16) and transaldolase
(EC:2.2.1.2), was also observed in these patients. Genes
associated with metabolic pathways linked to the bio-
synthesis of secondary metabolites ([Q]) such as succi-
nylbenzoic acid-CoA ligase (EC:6.2.1.26), or those
associated with amino-acid transport and metabolism ([E])
such as phosphoribosylformimino-5-aminoimidazole car-
boxamide ribotide isomerase (EC:5.3.1.16) and glutamate
synthase (EC:1.4.1.14) were also modified. Intriguingly, all
of these genes showed the strongest association with the
fam(P+V/O+ C) ratio (Fig. 4a, enzyme names in red).
More importantly, projection of these enzymes onto the
Kyoto Encyclopedia of Genes and Genomes (KEGG)
metabolic pathways map identified central metabolism as
the main process associated with the fam(P+V/O+ C)
ratio. Among them, glyocoside hydrolase and glutamate
synthase were of particular interest because of their func-
tional roles in glycolysis activation and succinate produc-
tion via the GABA shunt pathway. Also worthy of mention
was the negative association of fam(P+V/O+ C) ratio
with ribulokinase and transaldolase, which also could pro-
mote glycolysis through inhibition of the pentose phosphate
pathway (Fig. 4b). Mapping of the main enzymes positively
or negatively correlated with fam(P+V/O+C) ratio
uncovered a clear connection between their functional fea-
tures and succinate metabolism (adapted from KEGG
metabolic pathways) (Supplementary Figure 3B).
In conclusion, our study reveals for the first time a strong
association between microbial community, gene composi-
tion, and metabolism and circulating succinate levels in
humans. Although it has been recently shown that
Table 1 Anthropometric and analytical characteristics in the cohort V
Follow-up study (cohort V)
Group 1 Group 2 p-Value
ΔRatio P+V/C+O −1.14± 1.29 2.83± 3.20 0.002
n 8 11
Sex (females/males) 6/2 4/7 0.096
ΔSuccinate (mM) −25.19± 27.11 12.33± 32.75 0.017
ΔWeight (kg) −0.25 (−19.1 to 3.47) 1.8 (−1 to 3.8) 0.351
ΔBMI (kg/m2) 0.15 (−3.35 to 1.42) 0.30 (−0.4 to 1.3) 0.840
ΔWaist (cm) 8 (−39 to 11) 8 (4.75 to 10.5) 0.475
ΔHip (cm) 2 (−33 to 6) 3 (−0.5 to 3.75) 0.887
ΔSBP −0.71± 23.73 3.20± 16.56 0.693
ΔDBP −1.71± 13.74 6.8± 11.50 0.185
ΔGlucose (mg/dl) −1± 7.78 6± 6.15 0.042
ΔCholesterol (mg/dl) 6.12± 30.60 −4.09± 22.83 0.415
ΔHDL cholesterol (mg/dl) 2.87± 12.91 0.55± 7.12 0.620
ΔTriglycerides (mg/dl) 1.61± 21.61 6.63± 27.56 0.675
ΔHb1ac (%) 0.41± 0.70 0.4± 0.68 0.969
ΔPrevotellaceae −3.66± 4.29 6.21± 7.68 0.005
ΔVeillonellaceae −0.44± 1.89 −0.7± 1.38 0.728
ΔOdoribacteraceae ND ND –
ΔClostridaceae 0.26 (−0.66 to 0.44) −1.1 (−2.82 to –0.58) 0.039
Data are presented as mean± SD or median (25th–75th), as appropriate. Differences were analyzed by the unpaired t-test (normal distribution) or
Mann–Whitney U-test (data not-normally distributed). Group 1 (patients ratio decreases at the end of follow-up) and Group 2 (patients ratio
increases at the end of follow-up). A p-value <0.05 was considered significant
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, ND not detected
Bold values represent those with statistically significant differences
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microbiota-derived succinate induces metabolic benefits by
acting as an intestinal gluconeogenic substrate in germ-free
mice [16], some caution should be exercised when
extrapolating from mouse model data to humans. Moreover,
a recent meta-analysis has suggested that in humans, the
association between specific gut microbiota and obesity is
Fig. 4 Associations of gut
microbiota interactions,
circulating succinate levels and
metabolic bacterial functions. a
Spearman’s rank correlation
between 64 genes encoding
metabolic enzymes and fam(P+
V/O+ C) ratio, circulating
succinate levels, Prevotellaceae,
Veillonellaceae, and




according to KEGG database;
[C] Energy production and
conversion; [E] Amino-acid
transport and metabolism; [F]
Nucleotide transport and
metabolism; [G] Carbohydrate
transport and metabolism; [H]
Coenzyme transport and
metabolism; [I] Lipid transport
and metabolism; [P] Inorganic
ion transport and metabolism
and [Q] Secondary metabolites,
biosynthesis and catabolism. b
Positive and negative
associations with the fam(P+V/
O+ C) ratio and metabolic
enzymes as adapted from the
KEGG metabolic pathways. See
also Supplementary Table S4
and Table 1 for all clinical
characteristics of cohort V
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smaller than that detected in mice and by most microbiome
studies in humans [74]. Although the physiological effects
of such modest differences are far from clear, they might
become more apparent at the level of specific gene tran-
scripts or metabolites. In this line, our study uncovers a
clear association between succinate levels and obesity-
related metabolic disturbances, similar to that found in other
CVD risk factors [7–11, 16, 75]. Clearly, although such an
increase does not necessarily qualify succinate as a disease-
causing metabolite, its participation in the pathophysiology
of obesity should not be entirely ruled out. Indeed, our data
show a significant increase of glycemia in those patients
who presented an increase in circulating succinate asso-
ciated with changes in gut microbiota. Although engage-
ment of succinate with its receptor has emerged as a link
between metabolic stress and inflammation [4–6], it is still
unclear whether succinate serves as a “harmful” signal or
might have a protective role by acting as alarmin [76].
Furthermore, similar to what is seen with other microbial
metabolites such as SCFAs, the beneficial and/or detri-
mental effects of succinate might depend on the amount
synthesized [77, 78]. Although it is evident that further
studies are required to prove causality, we hypothesize that
obesity-related dysbiosis along with increased gut perme-
ability might account for the higher levels of circulating
succinate found in obese subjects. This may explain why
colonization of germ-free mice with a probiotic succinate
producer strain under normal conditions of intestinal per-
meability increases cecal, but not circulating, succinate
levels [16]. Thus, we propose that modulation of fam(P+
V/O+C) ratio in a pathological condition of increased
intestinal permeability such as obesity will impact circu-
lating succinate levels. Under this scenario, it should be
considered that systemic succinate could act as a hormone-
like metabolite, signaling through SUCNR1. How such
levels impact host metabolism underlying obesity-related
co-morbidities or whether manipulation of gut microbiota,
specifically by increasing succinate-consuming families,
might improve metabolic disturbances in obese patients are
some of the open questions that should be explored in future
work. Indeed, host or even dietary sources of succinate
should not be dismissed. Our present findings point to
succinate as a microbiota-derived metabolite with a poten-
tial role in obesity and metabolic-associated cardiovascular
disorders, and strengthen the importance of microbial
communities and their interactions when microbiota-derived
bioactive compounds are studied.
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